Loading...
01/11 06:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed picture. Financial performance shows steady growth and positive trends, but guidance is modest, and there are concerns about gross margins and restructuring costs. The Q&A section reveals stable market share and strategic initiatives, but lacks specific guidance and details, which may cause investor uncertainty. The overall sentiment is neutral, with neither strong positive nor negative indicators to suggest significant stock price movement.
Global Sales $3.2 billion, with sales growth of 3.3% compared with the second quarter of 2024. Constant currency sales grew 2.7% with 0.6% attributable to foreign currency exchange and 0.8% growth from acquisitions.
GAAP Operating Margin 4.67%, a decrease of 42 basis points compared with the prior year GAAP operating margin.
Non-GAAP Operating Margin 6.96%, a decrease of 79 basis points compared to the prior year non-GAAP operating margin, driven by lower gross margins within the U.S. Distribution business due to lower glove pricing as well as targeted initiatives to accelerate growth in market share.
GAAP Net Income $86 million or $0.70 per diluted share. This compares with prior year GAAP net income of $104 million or $0.80 per diluted share.
Non-GAAP Net Income $135 million or $1.10 per diluted share. This compares with prior year non-GAAP net income of $158 million or $1.23 per diluted share.
Adjusted EBITDA $256 million compared with second quarter 2024 adjusted EBITDA of $268 million.
U.S. Dental Merchandise Sales Declined 1.2%, resulting from increased volume offset by lower product pricing.
U.S. Dental Equipment Sales Declined 4.7%, resulting from economic uncertainty beginning in May. Both traditional and digital equipment sales growth declined.
U.S. Medical Distribution Business Sales Grew by 6.3%, reflecting increased patient traffic and strong performance in the Home Solutions business.
International Dental Merchandise Sales Grew 1.9% or 0.5% in constant currency and was impacted by the timing of Easter.
International Dental Equipment Sales Grew 12.1% or 9.1% in constant currency, driven by strong sales growth in Canada, Germany, and Australia and New Zealand.
Global Value-Added Service Sales Grew 3.6%. Sales growth was impacted this quarter by lower sales in the Practice Transitions business, partially a result of a tough comparison in the prior year.
Global Specialty Products Group Sales Grew 4.2% or 3.3% in constant currency. Implant and Biomaterial business experienced solid growth, including double-digit growth in value implants and low single-digit growth in premium implants.
Global Technology Group Sales Grew 7.4% or 6.6% in constant currency. U.S. sales growth was driven by Revenue Cycle Management and Practice Management software with double-digit growth in Ascend. Internationally, sales growth was primarily driven by Dentally Cloud-Based Practice Management solutions.
Operating Cash Flow $120 million in the second quarter of 2025. This quarter, additional inventory was invested in the U.S. as part of a plan to mitigate the effects of tariff increases.
Innovative products and solutions: Specialty Products and Technology groups delivered strong results driven by innovative products and solutions.
New global e-commerce platform: Launched henryschein.com in the U.K. and Ireland, with a phased launch in North America, starting in Canada and the U.S.
Dental implants and biomaterials: Accelerating growth in dental implants and biomaterials, including double-digit growth in value implants.
Cloud-based platforms: Strong growth in cloud-based platforms like Dentrix Ascend and Dentally, with over 10,000 customers.
Market share gains: Continuing to gain market share across the portfolio, supported by a price-value commercial model.
International growth: Strong sales growth in Brazil, Canada, and Europe, particularly in traditional dental equipment.
Cost efficiencies: Implemented initiatives to rightsize expenses, consolidate manufacturing facilities, and achieve $100 million in savings by year-end.
AI and technology integration: Introducing AI solutions to streamline processes and enhance customer experience.
BOLD+1 Strategic Plan: Advancing the BOLD+1 strategy to drive customer satisfaction and financial goals.
Partnership with KKR's Capstone: Engaged to enhance distribution gross margins and accelerate sales of owned products.
Leadership transition: CEO Stanley M. Bergman announced retirement, with a focus on succession planning and leadership development.
Lower Margins in U.S.: The company experienced lower margins in the U.S. due to reduced glove pricing and time-limited targeted sales initiatives, which could impact profitability.
Tariff-Related Market Uncertainty: U.S. dental equipment sales were temporarily impacted by market uncertainty related to tariffs, which could affect future sales and customer confidence.
Lower Average Selling Prices: Growth in digital equipment sales came at lower average selling prices, potentially impacting revenue growth.
Restructuring Costs: The company incurred $23 million in restructuring expenses in Q2 2025, which could strain financial resources in the short term.
Economic Uncertainty: Economic uncertainty beginning in May led to a decline in U.S. dental equipment sales, which could continue to affect customer purchasing behavior.
Practice Transitions Business Volatility: Lower sales in the Practice Transitions business due to high prior-year comparables could impact high-margin revenue streams.
Orthodontics Business Challenges: The orthodontics segment continues to face challenges, with sales declining year-over-year, albeit at a slower pace.
Increased Operating Expenses: Higher operating expenses due to acquisitions, foreign exchange, and technology investments could pressure margins.
Tariff Mitigation Inventory Costs: Additional inventory investments in the U.S. to mitigate tariff effects could tie up capital and impact cash flow.
Full Year Guidance: The company is maintaining its full-year guidance, reflecting earnings weighted to the second half of the year. They expect 2025 to be the base year for achieving their long-term goal of high single-digit to low double-digit earnings growth.
Value Creation Initiatives: Two value creation projects have been initiated to enhance distribution gross margins and increase efficiencies. These projects are expected to start producing results in early 2026, supporting the company's financial goal of high single-digit to low double-digit earnings growth.
E-commerce Platform Launch: The phased launch of the new global e-commerce platform, henryschein.com, is underway in North America and will continue into the fourth quarter of 2025.
U.S. Dental Equipment Sales: Sales were temporarily impacted by market uncertainty related to tariffs but are expected to grow in the second half of the year due to a rebound in new office design activity and equipment backlog recovery.
Global Specialty Products Group: Sales growth in dental implants and biomaterials is accelerating, with double-digit growth in value implants. The expansion of the BioHorizons sales force in the U.S. is expected to drive continued sales growth.
Global Technology Group: Sales are accelerating, driven by strong growth in cloud-based platforms and revenue cycle management offerings. The company expects continued growth in annual recurring SaaS subscription revenues.
Restructuring and Cost Savings: The company expects to achieve annual run-rate savings of over $100 million by the end of 2025, with further enhanced profitability beginning in 2026 due to new value creation initiatives.
2025 Financial Guidance: Non-GAAP diluted EPS is expected to be in the range of $4.80 to $4.94. Adjusted EBITDA is expected to grow in the mid-single digits, and total sales growth is projected to be 2% to 4% over 2024.
Share Repurchase: During the second quarter of 2025, the company repurchased approximately 3.7 million shares of common stock at an average price of $70.88 per share for a total of $259 million. This included approximately 3.1 million shares of common stock under the previously announced accelerated stock repurchase plan at an average price of $71.60 per share for a total of $223 million, which followed the company's sale of 3.3 million shares of common stock at an average price of $76.10 per share for a total of $250 million to KKR. The ASR plan was completed in July. In addition to the ASR plan, the company repurchased approximately 0.5 million shares of common stock at an average price of $67.36 per share for a total of $36 million. At the end of the quarter, $432 million was authorized and available for future stock repurchases plus a further $27 million authorized under the ASR, which has now been completed.
The earnings call reflects a positive sentiment with strong financial performance, strategic growth initiatives, and stable market conditions. Despite some uncertainties in guidance, the company shows solid growth in key segments, optimistic future earnings, and market share gains. The involvement of KKR and the stabilization of margins further support a positive outlook. The Q&A session highlighted management's confidence in continued growth and strategic advancements, although some specifics were withheld. Overall, the positive aspects outweigh the uncertainties, suggesting a positive stock price movement in the near term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
